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Abstract: CONTEXT Signs and symptoms of Cushing’s syndrome (CS) overlap with common diseases,
such as the metabolic syndrome, obesity, osteoporosis, and depression. Therefore, it can take years to
finally diagnose CS, though early diagnosis is important for prevention of complications. OBJECTIVE
The aim of this study was to assess the time span between first symptoms and diagnosis of CS in
different populations in order to identify factors associated with an early diagnosis. DATA SOURCES A
systematic literature search via PubMed was performed to identify studies reporting on time to diagnosis
in CS. In addition, unpublished data from patients of our tertiary care center and 4 other centers were
included. STUDY SELECTION Clinical studies reporting on the time to diagnosis of CS were eligible.
Corresponding authors were contacted to obtain additional information relevant to the research question.
DATA EXTRACTION Data were extracted from the text of the retrieved articles and from additional
information provided by authors contacted successfully. From initially 3326 screened studies 44 were
included. DATA SYNTHESIS Mean time to diagnosis for patients with CS was 34 months (ectopic CS:
14 months; adrenal CS: 30 months; and pituitary CS: 38 months; p<0.001). No difference was found for
gender, age (</฀ 18 years), and year of diagnosis (before/after 2000). Patients with pituitary CS had
a longer time to diagnosis in Germany than elsewhere. CONCLUSIONS Time to diagnosis differs for
subtypes of CS but not for gender and age. Time to diagnosis remains to be long and requires to be
improved.
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Precis: A systematic literature and meta-analysis was performed to assess the time 
to diagnosis in Cushing's syndrome (CS). Significant differences for different 
su    e  of C  hin ’    nd o e we e fo nd. 
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Context: Signs and symptoms of C  hin ’    nd o e (CS) overlap with common 
diseases, such as the metabolic syndrome, obesity, osteoporosis, and depression. 
Therefore, it can take years to finally diagnose CS, though early diagnosis is 
important for prevention of complications.  
Objective: The aim of this study was to assess the time span between first 
symptoms and diagnosis of CS in different populations in order to identify factors 
associated with an early diagnosis. 
Data Sources: A systematic literature search via PubMed was performed to identify 
studies reporting on time to diagnosis in CS. In addition, unpublished data from 
patients of our tertiary care center and 4 other centers were included. 
Study Selection: Clinical studies reporting on the time to diagnosis of CS were 
eligible. Corresponding authors were contacted to obtain additional information 
relevant to the research question.  
Data Extraction: Data were extracted from the text of the retrieved articles and from 
additional information provided by authors contacted successfully. From initially 3326 
screened studies 44 were included.  
Data Synthesis: Mean time to diagnosis for patients with CS was 34 months 
(ectopic CS: 14 months; adrenal CS: 30 months; and pituitary CS: 38 months; 
p<0.001). No difference was found for gender, age (</≥ 18 years), and year of 
diagnosis (before/after 2000). Patients with pituitary CS had a longer time to 
diagnosis in Germany than elsewhere. 
Conclusions: Time to diagnosis differs for subtypes of CS but not for gender and 

















































































































































































C  hin ’    nd o e (CS) i  a  a e, potentially life-threatening endocrine disease 
causing, among others, metabolic, psychiatric, musculoskeletal and cardiovascular 
comorbidities 1. If left untreated it is associated with increased mortality, mainly due 
to cardiovascular and infectious complications, but even in appropriately treated CS 
mortality remains elevated 2. CS is mostly ACTH dependent, the consequence of 
corticotroph pituitary adenoma or ectopic ACTH secretion from neuroendocrine 
tumors. Approximately 20% of cases are ACTH independent due to autonomous 
cortisol production from adrenal sources. Chronically elevated glucocorticoid 
concentrations cause the characteristic phenotype, such as weight gain, moon face, 
buffalo hump, muscle weakness, bruisability, skin atrophy, striae rubrae, menstrual 
irregularities, hirsutism, acne and co-morbidities like diabetes mellitus, hypertension, 
hypercholesterolemia and osteoporosis 3. Due to the rareness of CS and because 
these symptoms overlap with other non CS conditions it can take many years to 
diagnose CS in a given patient 4. The  ecen  o e i   ‘e ide ic’ causes additional 
challenges to distinguish the few patients with true CS from those with a metabolic 
syndrome. As the duration of hypercortisolism appears to be the most relevant 
determinant for the degree of morbidity and preterm mortality, it is important to 
establish the diagnosis as early as possible 5. Also, there is increasing evidence that 
restitution of symptoms and body changes after surgery depends on the duration of 
CS 6. Duration of CS is an important factor influencing  a ien ’  recovery after 
successful surgery, especially regarding psychiatric morbidity 7, which coincides with 
changes in brain structure and function sustained during exposure to glucocorticoid 
excess 8. We hypothesized, that the time span from first symptoms to final diagnosis 



















































































































improved biochemical screening tools for CS or also increasing awareness for rare 
diseases 9. The aim of this study was to assess the time between first symptoms and 
diagnosis of CS in different populations and geographic backgrounds and from 
different decades by performing a systematic literature review and meta-analysis 
inc  din  addi iona   e      f o   he Ge  an C  hin ’   e i    . By that we wanted 
to identify factors, which are associated with early or late diagnosis.  
METHODS and PATIENTS  
Study selection 
We performed a systematic literature search in PubMed database and Cochrane 
library according to the Meta-analyses of Observational Studies in Epidemiology 
(MOOSE) guidelines 10. We   ed  he  e   “C  hin ’    nd o e, C  hin    nd o e, 
C  hin ’  di ea e, C  hin  di ea e, pituitary ACTH hypersecretion” in the title or 
abstract to identify published articles reporting on C  hin ’    nd o e/disease in 
general. The literature search was performed in the last week of July 2018.  
Inclusion and exclusion criteria 
Studies were eligible for analysis, when data reporting on time to diagnosis was 
available as mean time +/- standard deviation. Reviews, case reports, guidelines, 
non-English literature and non-human studies were excluded. 
Data extraction 
Abstracts were screened carefully by one of the authors (GR) for clinical / patient-
based studies. If this was the case, the full-text manuscript was screened for content 
reporting on time to diagnosis in CS. To obtain data on mean time +/- standard 



















































































































studies to retrieve missing data. Furthermore, we asked authors to perform additional 
analysis of their data for different subtypes and gender (if available and possible). 
Authors of studies published before 2000 were not contacted because of a 
decreased likelihood to contact successfully. 
Munich cohort 
We analyzed the data of 172 patients (140 women and 32 men) with all subtypes of 
CS diagnosed and followed-up at Ludwig-Maximilian-University hospital tertiary care 
center between 1986 and 2018. Of all patients, 122 had pituitary CS (103 patients 
diagnosed after 2000), 18 ectopic CS and 32 adrenal CS. The study was performed 
accordingly to the Declaration of Helsinki. Written consent was given by all study 
participants.  
Definition of the time to diagnosis (onset between first symptom and diagnosis 
of CS/diagnostic delay) 
As in most studies this information was reported rather as a side information, the 
exact definitions of how the first symptom was defined was mostly not available. In 
studies with available definition on the first symptom, in general two different 
methods were used: either retrospective definition by the patient alone (e.g. in a 
questionnaire) or by defining the first symptoms in a clinical assessment by an 
endocrinologists. 
Definition of variables  
We analyzed subtype of CS (pituitary, ectopic and adrenal (excluding adrenal 
carcinoma, primary bilateral macronodular adrenal hyperplasia and primary 
pigmented nodular adrenocortical disease)), sex (female, male), age (children and 



















































































































2000). Analysis of different geographic regions was performed for countries with at 
least four studies available. The analysis for age, year of publication and geographic 
regions was done only in patients with pituitary CS due to the imbalance in the 
number of studies for different subtypes. 
Statistical analysis 
For statistical analysis of the Munich cohort IBM SPSS Statistics (version 21.0, IBM 
North America) was used. Metric variables are reported as mean ± standard 
deviation. Due to the low sample number non-parametric tests were used: Mann-
Whitney-U test for two unpaired groups and the Kruskal-Wallis test with subsequent 
Post-hoc analysis for more than two unpaired gro ps. P-values ≤0.05 were 
considered statistically significant. 
For the meta-analysis forest plots were generated to show mean time to diagnosis 
along with 95% confidence intervals (CI) for the different studies. To combine data 
from different studies for meta-analysis, random-effects models were fitted with 
inverse variance weighting. Mixed-effects models were used to investigate potential 
effects of different moderators like subtype of CS on time to diagnosis. P-values 
≤0.05 were considered statistically significant. Statistical analysis was performed 
using the rma (robust multi-array average) and forest functions of the package 
metafor (version 2.0) with R version 3.5.0 (www.r-project.org). 
RESULTS  
Time to diagnosis in the Munich cohort 
Time to diagnosis in the Munich cohort was in total 48 +/- 51 months. Considering the 
differential diagnosis, time to diagnosis in patients with adrenal CS was 50 +/- 48 



















































































































(p=0.022). Post-hoc analysis showed a significant difference for the mean time to 
diagnosis for ectopic and adrenal CS (p=0.039, ectopic and pituitary (p=0,024) and a 
non-significant difference for adrenal and pituitary CS (p=1). Time to diagnosis in 
women with CS was 47 +/- 49 months, in men with CS 53 +/- 61 months (p=0.892). 
Time to diagnosis in 103 patients with pituitary CS diagnosed after 2000 was 52 +/- 
53 months, in 19 patients with pituitary CS diagnosed before 2000 38 +/- 47 months 
(p=0.121). Data is given in mean +/- SD. 
Included studies 
We identified a total of 3325 studies. 71 of these studies contained information on 
time to diagnosis/duration of symptoms in CS. 6 studies were removed due to 
overlapping or identical patient cohorts. 34 studies presented data as mean time +/- 
standard deviation. 11 lead authors of these already eligible studies were contacted 
to get additional information (e.g. gender/subtype-related data). The other 31 studies 
expressed data not as mean time +/- standard deviation (e.g. median and range or 
other) and were therefore not eligible. 6 of them were published before the year 
2000. We contacted 25 lead authors of these initially not eligible studies to obtain 
data presented as mean time +/- standard deviation. Of all 36 contacted authors, 13 
did not respond, 6 responded but could not provide data, and 17 provided additional 
data. Four of these 17 authors provided us with unpublished data of 1336 patients 
from their centers (Marco Losa from San Raffaele, University Vita-Salute, Milan, Italy; 
Atanaska Elenkova from Medical University, Sofia, Bulgaria, Márcio Carlos Machado 
from Universidade de São Paulo, Brasil; Felicia Alexandra Hanzu from Hospital Clinic 



















































































































In total, data from 44 studies (including our patient cohort) collected between 1969 
and 2018 and containing appropriate data on time to diagnosis of 5367 patients were 
analyzed in this meta-analysis. Studies were heterogeneous regarding subtype of 
CS, gender, age and time of recruitment (Table 1; Figure 1). 
Time to diagnosis according to subtype 
Meta-analysis of all included studies showed a mean time to diagnosis of 34 months 
(95% CI 30-38) without stratifying for subtypes, gender, age, recruitment time and 
geographical background (Figure 1 in 11). Among the studies stratifying for CS 
subtypes, mean time to diagnosis was 30 months (95% CI 24-36) in adrenal CS, 14 
months (95% CI 11-17) in ectopic CS and 38 months (95% CI 33-43) in pituitary CS 
(p<0.001). Post-hoc analysis showed a significant difference for the mean time to 
diagnosis for ectopic and adrenal CS (p=0.0025), ectopic and pituitary (p<0.0001) 
and a non-significant trend for adrenal and pituitary CS (p=0.098) (Figure 2). The 
majority of patients with ectopic CS had bronchial or thymic carcinoids, some 
gastroenteropancreatic neuroendocrine tumors. Small cell lung carcinomas (SCLC) 
were present in 0-27% of the series, with the largest series compromising 110 of 
which 4% had SCLC. 
Impact of sex 
Overall, mean time to diagnosis in female patients with CS (all subtypes) was 33 
months (95% CI 27-38) compared to 31 months (95% CI 26-36) in males (p=0.66) 
(Figure 2 in 11), with similar distribution according to subtypes in both sexes. 
Time to diagnosis according to age in pituitary CS 
We hypothesized that mean time to diagnosis might be shorter in pediatric CD (age 



















































































































former. However, in the nine pediatric studies mean time was 33 months (95% CI 29-
38) versus 39 months (95% CI 33-45) in adult patients (p=0.37) (Figure 3 in 11).  
Impact of the year of publication on the time to diagnosis in pituitary CS 
We further wondered whether the publication year of the study might have impact on 
time to diagnosis. Based on the assumption that secular trends in disease 
awareness, improved diagnostic tools and phenotypic presentation might influence 
the speed in identifying CS we chose the year 2000 as a cut-off. Surprisingly, studies 
published before 2000 had an identical latency (37 months, 95% CI 29-46) than 
studies published after 2000 (37 months, 95% CI 31-44) (p=0.92) (Figure 4 in 11).  
Time to diagnosis in pituitary CS according to geographic regions 
Due to the fact that studies from all over the world were included, we wondered 
whether differences in the mean time to diagnosis in the largest subgroup of patients 
with pituitary CS could be identified. Countries with at least 4 studies available were 
Germany, Italy, United Kingdom (UK) and the United States of America (USA). 
Mean time to diagnosis was 34 months (95% CI 29-40) for USA, 35 months (95% CI 
26-45) for Italy, 39 months (95% CI 27-51) for UK and 56 months (95% CI 43-68) for 
Germany (p=0.02). Post-hoc analysis showed significant differences for the mean 
time to diagnosis between Germany and USA (0.0038), Italy (p=0.0052) and UK 
(p=0.039) and non-significant differences for other comparison (Figure 3; Table 2). 
DISCUSSION 
We report here the meta-analysis of the time to diagnosis from 44 studies, to which 
our own unpublished series was added. The results of our own cohort is in line with 



















































































































We herein demonstrate that the mean time to diagnosis of CS in general is 34 
months. Patients with ectopic CS had a significantly shorter time to diagnosis than 
patients with adrenal and pituitary CS. Patients with adrenal CS have a trend to 
shorter time to diagnosis than patients with pituitary CS without reaching statistical 
significance. It seems reasonable to speculate that ectopic CS due to aggressive 
ACTH-producing tumors is associated with a more severe clinical phenotype 
developing much more rapidly and causing more life-threatening complications 
(including severe hypokalemia and hyperglycemia)12, even though only a minority of 
patients in our meta-analysis had small cell lung cancer, an entity with a particular 
aggressive clinical phenotype.  
The non-significant difference in the time to diagnosis between adrenal and pituitary 
CS is not fully understood. This finding contrasts with the significantly faster recovery 
of adrenal insufficiency in pituitary CS compared to adrenal CS 13, which would rather 
imply a longer duration of hypercortisolism and time to diagnosis in adrenal CS. The 
more complicated biochemical testing and tumor localization (e.g. sinus petrosus 
catheterization) in pituitary CS compared to the usually rather straight forward 
diagnostic work-up in adrenal CS might be a possible explanation to this fact. 
On the other hand the longer exposure to high glucocorticoid levels in pituitary CS 
could contribute to the fact, that patients with pituitary CS have significantly lower 
disease-specific quality of life (CushingQoL) scores compared to patients with 
adrenal CS 14. Together with the risk of recurrence and pituitary deficiency it can 
explain the increased long-term emotional instability observed in this subtype. This 
underscores the necessity of careful screening for psychiatric comorbidities in every 
Cushing patient. In addition, psychological counseling by health care professionals 



















































































































Gender does not seem to have a relevant impact on the time to diagnosis. It confirms 
the results of Kreitschmann-Andermahr and colleagues, who did not find a difference 
in the overall diagnostic delay between females and males. These authors, however, 
showed that females contacted physicians earlier than males whereas in male 
patients the physician was the one recognizing symptoms of CS 16.  
Surprisingly, we did not identify significant differences in time to diagnosis according 
to age in pediatric CD versus adult CD (33 versus 39 months, p=0.37). This is 
unexpected since hypercortisolism in children comes with severe growth retardation, 
a feature, which is difficult to overlook. In addition, children with CD gain weight, 
which makes CD the only condition in pediatrics, where curves for height and weight 
on the growth chart deviate in different directions.  
In addition, we did not identify a trend towards earlier diagnosis in more recently 
treated patients in comparison to studies published before the year 2000. We explain 
this by a higher prevalence of advanced obesity nowadays, which besides the 
obvious weight gain is the condition with the most overlapping symptoms with CS 
(moon facies, diabetes mellitus, hypertension, menstrual irregularities). In our 
experience, patients with confirmed CS in fact have a lower BMI compared to 
patients with suspected, but biochemically not confirmed CS (~30kg/m2 vs. 33 kg/m2; 
unpublished data). Therefore, it is good clinical practice that primarily not obesity, but 
the presence of unusual features for age (such as osteoporosis or hypertension), 
multiple progressive features, and signs and symptoms of protein catabolism (i.e. 
myopathy) should rise the suspicion for CS 3,4. A diagnostic score of clinical variables 



















































































































Novel diagnostic approaches such as automatic face recognition using computerized 
techniques were thought to be useful in early recognition of body changes, but have 
lately turned out to be of limited value 18. 
Strengths and limitations: We were able to include a large body of studies and obtain 
additional data for those studies in which the data format was not appropriate. This 
makes this study the largest ever published on this subject. Most of the limitations 
are inherent to this type of meta-analysis. A relevant limitation is the fact, that in most 
of the included publications the information about time to diagnosis / diagnostic delay 
was not the primary endpoint of the study. In such a scenario, there is almost always 
a lack of a definition of how the first symptom was defined. Moreover, when it was 
described, different methods and definitions were used to assess the first symptoms: 
Some authors used questionnaires in order to retrospectively assess first symptoms, 
whereas other authors defined first symptom related to CS by clinical assessment by 
an endocrinologist. As cognitive deficits and emotional disturbances may be present 
in patients with CS their definitions might not be accurate. In summary, different 
definitions and perspectives (patients/physicians) were used to assess the time from 
first symptom to final diagnosis, which might have led to rather strict (with a shorter 
time to diagnosis) or permissive (longer time to diagnosis) definitions. We 
nevertheless think that this is applying to all studies and did not change over time. In 
addition, as estimates for time to diagnosis were not the primary endpoints of the 
studies, publication bias seems rather unlikely for this meta-analysis.  
Different definitions of first symptom of CS might be also an explanation why time to 
diagnosis varied in different geographic regions. For example, the estimation of the 



















































































































by the patients themselves, which could explain the rather long time to diagnosis due 
to the cognitive and emotional impairment. 
In summary, the main finding of our study is twofold: first, there is a clear difference 
in the time to diagnosis depending on the subtype of CS, being shortest in ectopic 
CS; second, despite a multitude of improvements in the care of patients, we did not 
detect secular trends towards earlier diagnosis in pediatric patients or patients with 
more recent diagnosis. Although there may be methodical limitations to our meta-
analysis, this is clearly disappointing from both patients and physicians perspectives.  
It remains unclear how to shorten the time to diagnosis in CS. Patients with rare 
diseases in general and CS in particular face the problem of a delayed diagnosis. At 
the same time, CS is often wrongly suspected in cohorts with a low pre-test 
probability (such as obesity).  
On the other hand, published data and our own experience have shown that the 
  eva ence of C  hin ’    nd o e i   i nifican    hi he  a on   a ien s with 
uncontrolled diabetes mellitus and arterial hypertension, adrenal incidentalomas and 
osteoporosis 4. Consequently, these common diseases, especially when occurring 
together, may be subject to a preselection in the process of targeted search for this 
rare pathology especially in young patients. 
In our opinion it seems unlikely to educate non-endocrinologists on symptoms of CS. 
More effective measures could be to educate non-endocrine-specialists and general 
practitioners in pattern recognition: unusual presentations and dynamic 
developments (multiple progressive features especially of catabolic effects from 
hypercortisolism such as myopathy and skin atrophy) apply to many rare diseases 



















































































































In addition, there is a high need for simple and effective biochemical screening 
approaches 19. Current tests have significant sensitivity and specificity issues. 
Recently we showed that a seven steroid finger print from baseline plasma samples 
could nicely separate CS from rule-out CS. This study stokes the hope, that such a 
test (if validated) could be superior to currently used standard Cushing screening 
tests 20. 
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Table 1: Characteristics of the 44 included studies. Adr: Adrenal. Ect: Ectopic. N.a: not avalaible. Pit: Pituitary. 
Table 2: Post-hoc analysis with p-values for the time to diagnosis in pituitary CS according to geographic regions. 
Reference Year 
published 



















45 Adrenal: 8; 
Pituitary: 37 
UK Adults No 
McArthur
22




27 Pituitary USA Children No 
Bertagna
23




22 Adrenal USA Adults No 
Hotta
24
 1985 Single-Center N.a. 8 Adrenal: 3; 
Pituitary: 5 
 
Japan Adults No 
Sandler
25




51 Pituitary UK Adults No 
Magiakou
26




10 Ectopic: 1; 
Pituitary 9 
USA Children No 
Bochicchio
27




668 Pituitary Europe Adults No 
Magiakou
28
 1997 Single-Center N.a. 31 All (Adr: 5; Ect: 
3; Pit: 23) 
USA Children No 
Massoud
29




12 Pituitary UK Children No 
Robyn
30




6 Pituitary Australia Children No 
Invitti
31




393 All (Adr: 80; Ect: 
25; Pit: 288) 
Italy Adults No 
Selvais
32




21 Pituitary Belgium Adults No 
Flitsch
33
 2000 Prospective, 
Single-Center 
N.a. 19 Pituitary Germany Adults No 
Vella
34




16 Ectopic: 4; 
Pituitary: 12 
USA Adults No 
Faggiano
35
 2003 Prospective, 
single-center 
N.a. 25 Pituitary Italy Adults No 
Giraldi
36
 2003 Retrospective, 
multicentric 
N.a. 280 Pituitary Italy Adults No 
Johansson
37




15 Pituitary Sweden Adults No 
Salgado
38




25 Ectopic Brazil Adults No 
Bhansali
39


























































































































55 Adrenal: 11; 
Pituitary: 44) 
Spain Adults Yes 
Oliveira
41




15 Pituitary Brazil Children Yes 
Bolland
42




253 All (Adr: 45; Ect: 












33 Pituitary Germany Adults No 
Valassi
44






420 All (Adr: 107; 
Ect: 22; Pit: 291) 
Europe Adults Yes 
Lodish
45




57 Pituitary USA Children No 
Lonser
46









2014 Single-center N.a. 22 Pituitary Netherlands Adults Yes 
Zilio
48




84 Pituitary Italy Adults Yes 
Aranda
49







67 All (Adr: 8; Ect: 
2; Pit: 57) 
Spain Adults Yes 
Ghazi
50













176 Pituitary Germany Adults Yes 
Zielinski
51




10 Pituitary Poland Adults No 
Geer
52
 2016 Prospective, 
Single-center 
N.a.  30 Pituitary USA Adults No 
Machado
53







421 Ectopic: 49; 
Pituitary: 37  
Brazil Adults Yes 
Shapiro
54




39 Pituitary UK Children Yes 
Bansal
55




230 Pituitary India Adults Yes 
Davi
56




110 Ectopic Italy Adults Yes 
Johnston
57




101 Pituitary USA Adults Yes 
Sathyakumar
58
 2017 Retrospective 2006-
2015 

























































































































71 Pituitary Belgium Adults Yes 
Dogansen
60




35 All (Adr: 15; Ect: 
3; Pit: 17) 










520 All (Adr: 159; 
Ect: 13; Pit: 348) 










624 Pituitary Italy Adults Yes 
Rubinstein Unpublished 





172 All (Adr: 32; Ect: 
18; Pit: 122) 
Germany Adults  
 
Table 2:  
 Germany  Italy UK USA 
Germany X 0.0052 0.039 0.0038 
Italy 0.0052 X 0.61 0.96 
UK 0.039 0.61 X 0.57 





















































































































Figure 1: Study flow. 
Figure 2: Mean time to diagnosis according to subtype (adrenal, ectopic, pituitary).  
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